sWGS revealed altered genomic profiles with a positive tumor fraction (TF ≥ 3%) in most of the patients both at baseline (T0) and disease progression (T3): among the samples collected, 27 out of 32 (84.4%) and 19 out of 21 samples (90.5%) exhibited a positive TF at T0 and T3 respectively. This evidence concerns the gene TF and neoplasm.